AzTrials
AzTrials

Pancreas Fistula Abdominal DrainsFIDELNCT06468917

First-day Versus Early Drain Removal Following PD: a Randomized Controlled Trial

A study testing 1st day removal of abdominal drain in people with Pancreas Fistula Abdominal Drains, run by Casa di Cura Dott. Pederzoli at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Pancreatic surgery is a complex discipline with a high risk of post-operative morbidity such as pancreatic fistula (POPF) with variable impact on clinical outcome. Controversies on ID placement have emerged from both randomized and non-randomized clinical studies investigating its possible role in increasing POPF and… Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Pancreas Fistula Abdominal Drains
What is being tested?
1st day removal of abdominal drain
Could I receive a placebo?
No, everyone receives an active treatment
How many people
224 participants
Where
1 siteItaly
Study dates
1 Jun 2024to 30 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients (age ≥ 18 or < 85 years) undergoing elective pancreaticoduodenectomy providing informed consent.
  • Intraoperative low to moderate risk for POPF (ISGPS class A-B-C)
  • POD 1 DFA < 300U/L

Who cannot join

  • Age <18 or >85
  • Patients with high risk of developing pancreatic fistula (ISGPS class D)
  • Intraoperative positioning of external or internal pancreatic stent
  • POD 1 DFA ≥300
  • Sinister appearance of drain effluent (defined as dark brown to clear "spring water" fluid that looks like pancreatic juice contaminated) as mentioned in literature3-22
  • Early post-pancreatectomy hemorrhage
Show all 12Show fewer
  • Intraoperative conditions different from POPF risk, requiring prolonged intrabdominal drains
  • Previous bilio/pancreatic surgery
  • Allergy to drain materials
  • Significant coagulation disorders
  • Patients unable to provide informed consent.
  • Clinical suspect of another surgery-related fistula different than POPF

Trial locations and contacts

1 site in 1 country.

Italy1 site, 1 recruiting
  • Cdcpederzoli

    Peschiera del Garda, Verona, 37019

    isabella frigerio, MD, 00390456449187, isabella.frigerio@ospedalepederzoli.it

    Recruiting

Other trials in Italy

About this study

Official title: First-day Versus Early Drain Removal Following Pancreaticoduodenectomy: a Randomized Controlled Trial

Pancreatic surgery is a complex discipline with a high risk of post-operative morbidity such as pancreatic fistula (POPF) with variable impact on clinical outcome. Controversies on ID placement have emerged from both randomized and non-randomized clinical studies investigating its possible role in increasing POPF and postoperative morbidity. The optimal timing for drain removal after PD is still a subject of debate: most studies have shown that outcomes are best when ID are removed in postoperative day (POD) 3 when POPF is excluded.

AIM we aim to compare postoperative surgical outcomes after PD in patients with low/medium risk for POPF (ISGPS risk class A-B-C), who undergo POD1 drains removal versus POD3 removal.

Read more

Primary aim: 1) grade B/C POPF; 2) post-pancreatectomy hemorrhage (PPH). Secondary aims: occurrence of fluid collection, sepsis, SSI, need for reintervention, length of stay, CD>3, 90 days mortality, re-admission.

Study Design:

This is a randomized, controlled, open-label study. All patients will be randomized on POD1, using computer-generated randomization codes.

Group A: Drain removal on POD 1 (in case of POD 1 DFA< 300 U/L) Group B: Drain removal on POD 3 (in case of POD 1 DFA< 300 U/L)

Read the detailed description

Introduction Pancreatic surgery is a complex discipline with a high risk of post-operative morbidity such as pancreatic fistula (POPF) with variable impact on clinical outcome, fluid collection and hemorrhage. For such reason the intraoperative placement of intra-abdominal drains (ID) to early detect, mitigate, and manage post-operative complications is still considered to be a routine practice.

Controversies on ID placement have emerged from both randomized and non-randomized clinical studies investigating its possible role in increasing POPF and postoperative morbidity as well as prolonged hospital stay. According to Conlon et al the presence of drains failed to reduce either the need for interventional radiologic drainage or surgical exploration for intraabdominal sepsis and was associated with the development of more intra-abdominal abscesses, collections, or fistulas. Some authors report significantly higher postoperative abdominal complications after late removal of ID. A prolonged period of drain insertion is associated with a higher rate of postoperative complications with increased hospital stay and costs, not to mention that dislocation of intra-abdominal drains is an early and frequent event after major pancreatic resection.

The optimal timing for drain removal after PD is still a subject of debate: most studies have shown that outcomes are best when ID are removed in postoperative day (POD) 3 when POPF is excluded (given a specific cut off for drain fluid amylase, DFA).

Even though many authors advocate early ID removal to prevent intra-abdominal infection or fistula, in clinical practice many surgeons may feel more comfortable to maintain IDs for a prolonged period (more than 3 days) even when criteria for POPF or other abdominal complications are not met.

In some studies correlation between drain fluid amylase (DFA) in POD1 after pancreatic resections and development of POPF has been examined, defining ideal cut-off points ranging between 5.000U/L and 90 U/l3-17-20-21 (depending on intraoperative risk stratification) that can be used to achieve the best timing for drain removal.

AIM In this non-inferiority study, we aim to compare postoperative surgical outcomes after PD in patients with low/medium risk for POPF (ISGPS risk class A-B-C), who undergo POD1 drains removal versus POD3 removal.

Primary aim: occurrence of one or more pancreas-specific complications, defined according to ISGPS as:1) grade B/C POPF; 2) post-pancreatectomy hemorrhage (PPH).

Secondary aims: occurrence of fluid collection, sepsis, SSI, need for reintervention, length of stay, CD>3, 90 days mortality, re-admission.

Patients and Methods:

Study Design:

This is a randomized, controlled, open-label study. The Study will be registered in the International Standard Randomized Controlled Trial Registry.

All patients encountering inclusion criteria will be randomized on POD1, using computer-generated randomization codes.

Group A: Drain removal on POD 1 (in case of POD 1 DFA< 300 U/L) Group B: Drain removal on POD 3 (in case of POD 1 DFA< 300 U/L)

Operative technique and drains positioning:

Experienced pancreatic surgeons will be performing a standard pancreaticoduodenectomy pylorus-preserving and a Whipple procedure if lesion infiltrates the duodenum. After resection, anastomoses will be constructed on a single jejunal loop. Management of pancreatic stump consisting in single- or double-layer, end-to-side pancreatojejunostomy (PJ) with non-absorbable interrupted sutures. Given the low risk for pancreatic fistula, no externalized trans-anastomotic stent will be placed. End-to-side hepaticojejunostomy will be performed 20 cm distally to PJ with absorbable continuous or interrupted sutures, and end-to side duodenojejunostomy with absorbable interrupted sutures. Two perianastomotic open passive penrose (Easyflow) drains are placed at the end of the procedure close to biliary anastomosis and close to PJ anastomosis15.

In conclusion, we aim, through this randomized trial, to demonstrate that POD1 drains removal after PD is not inferior to POD3 removal in low and medium risk patients and, moreover, it could prevent delayed removal-related complications, helping to guide post-operative care and improve patient outcomes.

Being tested
1st day removal of abdominal drain
Keywords
pancreatic fistula pancreaticoduodenectomy drain fluid amylase

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1st day removal of abdominal drainBehavioural

    Also called 3rd day removal of abdominal drains

    once POPF is excluded in middle-low risk pancreatic resection, abdominal drains can be removed

Study groups in NCT06468917
Study groupRoleWhat they receive
Drain removal on POD 1Active comparatorin case of POD 1 DFA< 300 U/L
Receives: Behavioral: 1st day removal of abdominal drain
Drain removal on POD 3Active comparatorin case of POD 1 DFA< 300 U/L
Receives: Behavioral: 1st day removal of abdominal drain

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. occurrence of one or more pancreas-specific complications

    complications are defined according to ISGPS as:1) grade B/C POPF; 2) post-pancreatectomy hemorrhage (PPH).

    Measured: up to 90 days after surgery

Secondary outcomes (1)
  1. occurrence of general post operative complications

    occurrence of fluid collection, sepsis, SSI, need for reintervention, length of stay, CD>3, 90 days mortality, re-admission

    Measured: up to 90 days after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jun 2024
  2. Study start1 Jun 2024
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion30 Mar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a randomized, controlled, open-label study. The Study will be registered in the International Standard Randomized Controlled Trial Registry. All patients encountering inclusion criteria will be randomized on POD1, using computer-generated randomization codes. Group A: Drain removal on POD 1 (in case of POD 1 DFA\< 300 U/L) Group B: Drain removal on POD 3 (in case of POD 1 DFA\< 300 U/L)
Masking
None (open label)
Enrolment
224 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06468917
Sponsor's protocol ID
Cdcpederzoli
Acronym
FIDEL
Status last verified
Jun 2024
First submitted
16 Jun 2024
Last updated
21 Jun 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: after interim analysis

Questions about this trial

What is this clinical trial studying?

A study testing 1st day removal of abdominal drain in people with Pancreas Fistula Abdominal Drains, run by Casa di Cura Dott. Pederzoli at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact isabella frigerio, MD (00390456449187, isabella.frigerio@ospedalepederzoli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

occurrence of one or more pancreas-specific complications (time frame: up to 90 days after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jun 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in